Aerovate Therapeutics, Inc.
AVTE
$2.56
$0.051.99%
| Weiss Ratings | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.44 | |||
| Price History | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.99% | |||
| 30-Day Total Return | 8.02% | |||
| 60-Day Total Return | -4.48% | |||
| 90-Day Total Return | -1.92% | |||
| Year to Date Total Return | -4.66% | |||
| 1-Year Total Return | -91.20% | |||
| 2-Year Total Return | -86.45% | |||
| 3-Year Total Return | -84.16% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -91.71% | |||
| 52-Week Low % Change | 100.80% | |||
| Price | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $30.29 | |||
| 52-Week Low Price | $1.25 | |||
| 52-Week Low Price (Date) | Jun 20, 2024 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 72.75M | |||
| Enterprise Value | -5.45M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.45 | |||
| Earnings Per Share Growth | -14.63% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.95 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $2.56 | |||
| Enterprise Value/EBITDA (TTM) | 0.07 | |||
| Enterprise Value/EBIT | 0.07 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 28.61M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 443 2400 | |||
| Address | 930 Winter Street Waltham, MA 02451 | |||
| Website | www.aerovatetx.com | |||
| Country | United States | |||
| Year Founded | 2018 | |||
| Profitability | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -44.88% | |||
| Return on Equity | -- | |||
| Income Statement | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -74.31M | |||
| EBIT (TTM) | -74.60M | |||
| Net Income (TTM) | -69.63M | |||
| Net Income Avl. to Common (TTM) | -69.63M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 73.40% | |||
| EPS Diluted (TTM) | -2.45 | |||
| EPS Diluted Growth (Q YOY) | 74.25% | |||
| Balance Sheet | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 78.62M | |||
| Cash Per Share (Q) | $2.75 | |||
| Total Current Assets (Q) | 80.12M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 76.43M | |||
| Current Ratio (Q) | 20.929 | |||
| Book Value Per Share (Q) | $2.64 | |||
| Total Assets (Q) | 80.33M | |||
| Total Current Liabilities (Q) | 3.83M | |||
| Total Debt (Q) | 417.00K | |||
| Total Liabilities (Q) | 3.90M | |||
| Total Common Equity (Q) | 76.43M | |||
| Cash Flow | AVTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 56.03M | |||
| Cash from Financing (TTM) | 25.43M | |||
| Net Change in Cash (TTM) | 10.26M | |||
| Levered Free Cash Flow (TTM) | -48.54M | |||
| Cash from Operations (TTM) | -71.20M | |||
